STOCK TITAN

NextCure (NXTC) Financials

NXTC NASDAQ
Trailing 12 months to September 30, 2026
Revenue Not reported for the trailing 12 months
Net Income -$41.0M n/m YoY
EPS (Diluted) -$6.77 YoY not available
Operating Cash Flow -$42.8M n/m YoY
Market Cap $29.5M as of Nov 20, 2026
Price / Sales n/m no full year of revenue reported yet
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 5.4x on $5.5M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NXTC SEC filings page.

This page shows NextCure, Inc. (NXTC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NXTC FY2025

The research-led model remains cash-consuming, while shrinking assets make the financing structure progressively more constrained.

Operating cash flow was -$49.6M in FY2025 against a net loss of $55.8M. That cash outflow was worse than FY2024’s -$40.8M even as SG&A fell 19.2%, so lower overhead did not yet translate into better cash conversion.

Assets fell 37.9% to $50.2M in FY2025, shrinking the capital base. Liabilities represented 30.4% of assets versus 19.0% in FY2024, making the smaller balance sheet more liability-weighted.

R&D was $44.9M versus SG&A of $12.7M, making research the dominant reported cost commitment. R&D increased 8.3% while SG&A fell 19.2%, showing spending was being concentrated rather than broadly expanded.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for NextCure, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
1/6

NextCure, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

NextCure, Inc. reported a net loss of $55.8M while operations used $49.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income
-$6.8M
YoYn/m
QoQn/m
5Y CAGRn/m

NextCure, Inc. reported a net loss of $6.8M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$1.29
QoQn/m

NextCure, Inc. earned -$1.29 per diluted share (EPS) in Q3 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

EBITDA

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt
$8.7M
YoY+19.2%
QoQ-42.8%
5Y CAGR-25.0%

NextCure, Inc. held $8.7M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
5M
QoQ0.0%

NextCure, Inc. had 5M shares outstanding in Q3 2026. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-124.4%
YoY-87.9pp
QoQ-1.8pp
5Y change-117.2pp

NextCure, Inc.'s quarterly ROE was -124.4% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 87.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.8 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$4.5M
YoY-26.1%
QoQ-38.9%
5Y CAGR-19.7%

NextCure, Inc. invested $4.5M in research and development in Q3 2026. This represents a decrease of 26.1% from the same quarter a year earlier. Against the prior quarter it is down 38.9%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

NXTC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NXTC quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'25S-4/AQ3'2510-QQ2'2510-QQ1'2510-QQ4'24S-4/A
R&D Expenses$4.5M-26.1%$7.4M-69.2%$6.8M-13.4%$6.8M-23.6%$6.1M-30.0%$24.1M+94.0%$7.9M-30.7%$8.9M-24.7%
SG&A Expenses$4.4M+57.6%$2.6M-19.0%$3.3M-12.2%$3.0M-16.8%$2.8M-24.6%$3.2M-21.5%$3.7M-14.6%$3.6M-10.3%
Operating Income-$6.9Mn/m-$15.1Mn/m-$10.1Mn/m-$9.8Mn/m-$8.9Mn/m-$27.3Mn/m-$11.6Mn/m-$12.5Mn/m
Income Tax$0n/m$0n/m$0n/m$0$0n/m$0n/m$0n/mN/A
Net Income-$6.8Mn/m-$14.9Mn/m-$9.8Mn/m-$9.4Mn/m-$8.6Mn/m-$26.8Mn/m-$11.0Mn/m-$11.6Mn/m
EPS (Basic)-$1.29-$2.80-$1.87-$0.81-$3.22n/m-$11.29n/m-$4.70n/m-$4.92n/m
EPS (Diluted)-$1.29-$2.80-$1.87-$0.81-$3.22n/m-$11.29n/m-$4.70n/m-$4.92n/m
Diluted Shares (Avg)5M5M5MN/A3M+14.8%2M+1.9%2M+0.4%N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense.

NXTC Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NXTC quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'25S-4/AQ3'2510-QQ2'2510-QQ1'25FilingQ4'24S-4/A
Total Assets$9.7M-75.5%$22.6M-52.6%$38.0M-43.4%$50.2M-37.9%$39.6M-56.2%$47.7M-53.5%$67.1M-41.7%$80.9M-36.8%
Current Assets$9.7M-70.3%$22.3M-44.4%$31.7M-46.1%$43.7M-39.1%$32.6M-58.5%$40.0M-55.8%$58.9M-42.6%$71.8M-36.3%
Cash & Equivalents$8.7M+19.2%$15.3M+211.9%$15.2M-30.5%$26.0M-6.3%$7.3M-73.6%$4.9M-76.5%$21.8M+18.9%$27.7M+111.9%
Short-Term Investments$0-100.0%$4.8M-84.1%$14.6M-57.2%$15.8M-61.3%$21.8M-54.2%$30.4M-53.6%$34.0M-56.2%$40.9M-57.1%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$4.2M-73.7%$10.5M-34.7%$11.3M-0.2%$15.2M-1.0%$16.0M+8.2%$16.0M-6.4%$11.3M-30.0%$15.4M+13.0%
Current Liabilities$4.2M-61.8%$6.4M-40.5%$6.9M+20.1%$10.6M+10.4%$11.0M+26.8%$10.8M-0.5%$5.7M-40.1%$9.6M+39.1%
Non-Current Liabilities$0-100.0%$4.1M-22.9%$4.4M-21.1%$4.7M-19.6%$5.0M-18.2%$5.3M-16.7%$5.5M-15.1%$5.8M-13.7%
Total Equity$5.5M-76.7%$12.1M-59.0%$26.7M-52.2%$34.9M-46.6%$23.6M-68.7%$29.6M-65.3%$55.9M-43.6%$65.5M-42.8%
Retained Earnings-$467.5Mn/m-$460.7Mn/m-$445.8Mn/m-$436.0Mn/m-$426.5Mn/m-$417.9Mn/m-$391.1Mn/m-$380.1Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

NXTC Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NXTC quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'25S-4/AQ3'2510-QQ2'2510-QQ1'2510-QQ4'24S-4/A
Operating Cash Flow-$12.1Mn/m-$9.7Mn/m-$13.4Mn/m-$7.6Mn/m-$6.3Mn/m-$22.7Mn/m-$13.0Mn/m-$7.0Mn/m
Stock-Based Compensation$196K-67.3%$304K-48.2%$344K-74.8%N/A$600K-60.8%$587K-63.2%$1.4M-19.5%N/A
Investing Cash Flow$5.5M-36.3%$9.8M+160.3%$1.3M-81.7%$6.0M-13.7%$8.7M-52.5%$3.8M-69.1%$7.1M-60.3%$7.0M+67.2%
Financing Cash Flow$1Kn/m$22K$1.2M$20.3M+54745.9%$0n/mN/AN/A$37K-47.9%

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

NXTC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NXTC quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'25S-4/AQ3'2510-QQ2'2510-QQ1'2510-QQ4'24S-4/A
Return on Equity-124.4%-87.9pp-122.6%-32.1pp-36.7%-17.0pp-27.0%-9.3pp-36.5%-21.2pp-90.4%-72.4pp-19.7%-2.4pp-17.7%-5.1pp
Return on Assets-70.6%-48.8pp-65.8%-9.6pp-25.8%-9.4pp-18.8%-4.5pp-21.8%-9.0pp-56.2%-41.2pp-16.4%-1.5pp-14.3%-3.0pp
Current Ratio2.31-0.7x3.47-0.2x4.61-5.7x4.14-3.4x2.97-6.1x3.71-4.6x10.26-0.4x7.50-8.9x
Liabilities-to-Equity0.76+0.1x0.86+0.3x0.42+0.2x0.44+0.2x0.68+0.5x0.54+0.3x0.200.0x0.24+0.1x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
NextCure, Inc. NXTC FY2025 N/A -$55.8M N/A $29.5M —
Kalaris Therapeutics, Inc. KLRS FY2025 N/A -$43.4M N/A $30.5M —
Rein Therapeutics, Inc. RNTX FY2025 $0 -$49.9M N/A $29.1M —
ProMIS Neurosciences Inc. PMN FY2025 N/A -$39.7M N/A $28.4M —
Alterity Therapeutics Limited ATHE FY2026 N/A -$16.2M N/A $29.0M —
Edesa Biotech, Inc. EDSA FY2025 N/A -$7.2M N/A $27.0M —

Frequently Asked Questions

No, NextCure, Inc. (NXTC) reported a net loss of $41.0M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $55.8M.

NextCure, Inc. (NXTC) reported diluted earnings per share of -$19.65 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

NextCure, Inc. (NXTC) had EBITDA of -$55.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

NextCure, Inc. (NXTC) has a return on equity of -159.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

NextCure, Inc. (NXTC) recorded an outflow of $49.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

NextCure, Inc. (NXTC) had $50.2M in total assets as of fiscal year 2025, including both current and long-term assets.

NextCure, Inc. (NXTC) invested $44.9M in research and development during fiscal year 2025.

NextCure, Inc. (NXTC) had 4M shares outstanding as of fiscal year 2025.

NextCure, Inc. (NXTC) had a current ratio of 4.14 as of fiscal year 2025, which is generally considered healthy.

NextCure, Inc. (NXTC) had a liabilities-to-equity ratio of 0.44 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

NextCure, Inc. (NXTC) had a return on assets of -111.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

NextCure, Inc. (NXTC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $29.5M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

NextCure, Inc. (NXTC) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $29.5M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, NextCure, Inc. (NXTC) held $41.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $49.6M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

NextCure, Inc. (NXTC) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

NextCure, Inc. (NXTC) reported a net loss of $55.8M while operations used $49.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top